sb 203580 has been researched along with ondansetron in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (ondansetron) | Trials (ondansetron) | Recent Studies (post-2010) (ondansetron) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 3,380 | 1,216 | 994 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, FC; Liu, FW; Yu, HP | 1 |
1 other study(ies) available for sb 203580 and ondansetron
| Article | Year |
|---|---|
Ondansetron attenuates hepatic injury via p38 MAPK-dependent pathway in a rat haemorrhagic shock model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemokine CXCL1; Chemokine CXCL2; Cytokines; Disease Models, Animal; Enzyme Inhibitors; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-6; Liver Diseases; Male; Ondansetron; p38 Mitogen-Activated Protein Kinases; Peroxidase; Pyridines; Rats; Rats, Sprague-Dawley; Resuscitation; Serotonin Antagonists; Shock, Hemorrhagic; Tumor Necrosis Factor-alpha | 2011 |